Previous close | 69.55 |
Open | 69.85 |
Bid | 69.43 x 100 |
Ask | 69.83 x 100 |
Day's range | 69.50 - 70.31 |
52-week range | 36.99 - 70.81 |
Volume | |
Avg. volume | 136,032 |
Market cap | 1.468B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 81.99 |
EPS (TTM) | 0.85 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 79.80 |
ANI Pharmaceuticals (ANIP) concluded the recent trading session at $69.69, signifying a +0.2% move from its prior day's close.
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug (RLD) Levaquin®. The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. "New product launch execution remains a top priority for ANI as we c